The human in vivo evidence that the anti-PF4 response in VITT is neither related to the spike protein nor to SARS-CoV2 came from data collected in a cohort of 11 patients with a history of VITT and subsequent COVID-19. The gene discussed is PF4; the disease is COVID-19.